Page 1,549«..1020..1,5481,5491,5501,551..1,5601,570..»

‘Breakthrough’ drug could reverse vision loss caused by diabetes … – KENS 5 TV

Posted: May 18, 2017 at 11:40 am

The FDA has approved a new drug that could reverse the effects of diabetic macular edema, which is what causes blindness in people with diabetes.

Jeremy Baker, KENS 1:34 PM. CDT May 17, 2017

A new medication could help reverse diabetes vision loss. (Photo: KENS)

Diabetes is reportedly the number one cause of blindness in the United States. Until recently, there was no way to reverse it. However, a fairly new drug recently approved by the FDA is changing that.

"It was one of those things that's hard to believe," said Sonny Groves, a portrait photographer. He found out he had diabetes 20 years ago. "As the disease progressed, I had problems like neuropathy in the hands and feet, that sort of thing," Groves said.

His vision also started to go. That's when he was referred to the Medical Center Ophthalmology Associates.

"Better control of your blood sugar will give us better control of the back of your eye," said Dr. Michael Singer as he examined Groves' vision. Singer is the director of clinical trials at MCOA.

"Dr. Singer was the first one to notice I had any problems because he noticed tiny bleeders in my retina," Groves said.

"When tissues are deprived of oxygen, they scream for help. They send out a signal called VEGF," said Singer.

The VEGF sends new blood vessels to help the tissues, but that's not a good thing.

"Instead of being helpful, they are actually harmful. They cause swelling in the central part of your vision," Singer said.

In comes a drug called Lucentis.

"This is the first time the FDA has approved a drug like this to reverse the disease," Singer said. The usage is for diabetic retinopathy in patients either with or without diabetic macular edema. This latest approval broadens the diabetic retinopathy indication to include patients both with and without diabetic macular edema.

That disease is called diabetic macular edema. Lucentis is a shot given in the white of the eye after it is numbed. The typical Lucentis dose for diabetic retinopathy is 0.3 mg, which is slightly lower than the 0.5 mg dose used for other eye diseases.

"The process takes literally about two seconds and the results can be seen as early as three days," Singer said.

Groves said the results were amazing.

"When I started taking the Lucentis, it got better. The swelling that causes all of that stopped," Groves said.

"They go from a situation where they are not seeing as well to actually improving their vision and increasing activities they are able to do in their daily life," Singer said.

Now, thanks to Lucentis, Groves said he doesn't have to stop being a photographer.

Some of the side effects of Lucentis could be eye irritation, eye pain, dry eyes or some potentially serious side effects.

Uncommon side effects could reportedly include changes in vision and eye infections.

2017 KENS-TV

Follow this link:
'Breakthrough' drug could reverse vision loss caused by diabetes ... - KENS 5 TV

Posted in Diabetes | Comments Off on ‘Breakthrough’ drug could reverse vision loss caused by diabetes … – KENS 5 TV

Novelogics Biotechnology, Inc. & CDRD Partner to Advance Novel Cancer Treatment – Business Wire (press release)

Posted: May 17, 2017 at 1:42 pm

VANCOUVER, British Columbia--(BUSINESS WIRE)--Novelogics Biotechnology, Inc. announced today that it has entered into a research agreement with The Centre for Drug Research and Development (CDRD), Canadas national drug development and commercialization centre, to further characterize Novelogics' internally-developed antibody immunotherapy for treating cancer.

The proprietary technology behind Novelogics innovation involves discovery and development of monoclonal antibodies that target a protein that promotes immune suppression in cancer patients. It is predicted that this new therapy could treat a broad range of cancers, and because it works with the patients own immune system, it would be safer and less toxic with fewer debilitating side-effects.

CDRD will be analyzing the technology through custom in vitro assays that will help validate and identify their lead antibody and move it towards a Phase 1 clinical trial as early as 2019. The technology has recently shown preliminary evidence of tumour inhibition in a prostate cancer model and based on results from CDRDs research, it could be expanded to other cancer models.

Novelogics President and Chief Scientific Officer Dr. Wayne Cheney stated, We are excited to introduce our novel approach to treating cancer. Unlike other immunotherapies that function by modulating, inhibiting or blocking targets, our innovative drug works by intercepting. This is a new way of limiting the immune suppressive effects of the drug target, which offers a huge opportunity to make a difference in the fight against cancer. We look forward to a successful collaboration with CDRD and are thrilled to be working with their technical team of experts and state-of-the-art biologics facility.

CDRDs Head of Biologics Dr. Ismael Samudio commented, This work with Novelogics is an exciting opportunity for CDRD to apply our scientific expertise in NK cell biology and therapeutic antibodies to a technology that has very promising pre-clinical potential. This a great example of how CDRD is partnering with Canadian life sciences companies to advance promising discoveries and transform them into validated investments and improved health outcomes. By combining our expertise and specialized infrastructure, we aim to provide critical data to advance Novelogics technology and help bring new therapeutic treatments to market.

It is anticipated that a pre-clinical candidate antibody will be selected in 2017, and that further clinical development activities will follow.

About Novelogics Biotechnology, Inc.

Novelogics Biotechnology Inc. is virtual life sciences company utilizing expertise at a variety of Contract Research labs and is dedicated to developing innovative cancer treatments that harness the power of the immune system to help eradicate tumors more naturally. Their immunotherapy concepts focus on development of antibody therapeutics and have the potential to treat multiple cancer types without the side-effects associated with traditional cancer therapies. We anticipate the technology will be well-received by larger biotechnology and pharmaceutical companies seeking novel antibody immunotherapy treatments in this exciting area of cancer drug development. Novelogics has one mission in mind we want to create better cancer treatments. http://www.novelogics.com

Novelogics Biotechnology Inc. is a privately-owned corporation operating in Vancouver, Canada.

About The Centre for Drug Research and Development (CDRD)

CDRD is Canadas national drug development and commercialization centre working in partnership with academia, industry, government and foundations. CDRD provides the specialized expertise and infrastructure to identify, validate and advance promising discoveries, and transform them into commercially viable investment opportunities for the private sector and ultimately into new therapies for patients. Canadas Networks of Centres of Excellence Program has recognized CDRD as a Centre of Excellence for Commercialization and Research (CECR). http://www.cdrd.ca

See the article here:
Novelogics Biotechnology, Inc. & CDRD Partner to Advance Novel Cancer Treatment - Business Wire (press release)

Posted in Biotechnology | Comments Off on Novelogics Biotechnology, Inc. & CDRD Partner to Advance Novel Cancer Treatment – Business Wire (press release)

Reasons to Add Puma Biotechnology (PBYI) to Portfolio Now – Zacks.com

Posted: May 17, 2017 at 1:42 pm

On May 16, 2017, we issued an updated report on Puma Biotechnology, Inc. (PBYI - Free Report) .

Puma Biotechnology is a development-stage biopharmaceutical company focused on the development and commercialization of innovative treatments that enhance cancer care.

The company posted narrower-than-expected loss in the first quarter of 2017. Reported loss of $1.97 per share was also narrower than year-ago figure of $2.19. With no approved products in its portfolio at the moment, the company does not generate revenues yet. The company reported first-quarter results on May 10, 2017.

So far this year, Pumas shares have outperformed Zacks classified Medical-Biomed/Genetics industry. The companys shares have gained 4.1% while the industry registered an increase of 2.2%.

Puma has made significant progress with its lead candidate, neratinib. The candidate is currently under review in both the U.S. and the EU for HER2+ breast cancer. An approval would be a huge boost for the company given the immense commercial potential in the target market.

We note that several additional studies on neratinib targeting different types of breast cancer patient populations are currently underway. During the quarter, Puma presented encouraging data from several ongoing studies on neratinib at the annual meeting of the American Association for Cancer Research (AACR).

Puma also expects to achieve several milestones in the second quarter of 2017. These include additional data from the phase III study on neratinib in third-line HER2-positive metastatic breast cancer patients and data from a phase II study on neratinib in HER2-positive metastatic breast cancer patients with brain metastases.

However, dependence on the successful development of a single candidate may hurt the companys growth prospects in case of any adverse development or regulatory setback.

Moreover, lack of partnership deals could hamper progress of the candidate as the company has no sales, marketing or distribution capabilities.

Zacks Rank & Key Picks

Puma currently carries a Zacks Rank #2 (Buy). Other stocks in the health care sector that warrant a look include Aeglea BioTherapeutics (AGLE - Free Report) , VIVUS, Inc. (VVUS - Free Report) and MEI Pharma, Inc. (MEIP - Free Report) . While Aeglea carries a Zacks Rank #2, VIVUS and MEI Pharma sport a Zacks Rank #1 (Strong Buy). You can see the complete list of todays Zacks #1 Rank stocks here.

Aegleas loss per share estimates narrowed from $3.64 to $2.48 for 2017, over the last 60 days. The company posted positive earnings surprises in three of the four trailing quarters with an average beat of 20.75%.

VIVUSs loss per share estimates narrowed from 50 cents to 39 cents for 2017, over the last 30 days. The company posted positive earnings surprises in all of the four trailing quarters with an average beat of 233.69%.

MEI Pharmas posted positive earnings surprises in three of the four trailing quarters with an average beat of 66.56%. The companys shares gained 16% so far this year.

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>

Read more here:
Reasons to Add Puma Biotechnology (PBYI) to Portfolio Now - Zacks.com

Posted in Biotechnology | Comments Off on Reasons to Add Puma Biotechnology (PBYI) to Portfolio Now – Zacks.com

FDA warns of foot, leg amputations with J&J diabetes drug – Reuters

Posted: May 17, 2017 at 1:40 pm

Johnson & Johnson (JNJ.N) is required to add new warnings to its diabetes drug, Invokana, about the risk of foot and leg amputations, the U.S. Food and Drug Administration said on Tuesday.

Final results from two clinical trials showed leg and foot amputations occurred about twice as often in patients with type 2 diabetes treated with Invokana, known also as canagliflozin, as those given a placebo, the FDA said in an announcement posted on its website.

The warnings include a boxed warning, reserved for the most serious possible adverse events, the FDA said.

Invokana belongs to a relatively new class of type 2 diabetes drugs called SGLT-2 inhibitors, which help remove excess blood sugar through urine. Others in the class include Eli Lilly and Co's (LLY.N) Jardiance and AstraZeneca Plc's (AZN.L) Farxiga.

The FDA noted that results of one clinical trial showed that over the course of a year the risk of amputation in patients treated with Invokana was equivalent to 5.9 out of 1,000, compared with 2.8 out of 1,000 for patients given a placebo.

A second trial showed the risk of amputation was equivalent to 7.5 out of every 1,000 patients treated with Invokana compared with 4.2 out of every 1,000 patients given a placebo.

The agency said amputations of the toe and middle of the foot were the most common but that amputations involving the leg, below and above the knee, also occurred.

Untreated type 2 diabetes can cause blindness, nerve and kidney damage and heart disease.

(Reporting by Toni Clarke in Washington and Bill Berkrot in New York; Editing by Lisa Shumaker)

Concert Pharmaceuticals Inc said on Wednesday the U.S. Food and Drug Administration (FDA) imposed a clinical hold on a trial testing the company's drug to treat alopecia areata, a type of hair loss.

MUMBAI India's big drugmakers will need at least five more years to improve their manufacturing standards and data reliability to a level demanded by international regulators, said a senior industry official.

Overweight and obese people who shed a lot of excess pounds may have less damage in their knee joints than their counterparts who dont lose weight, a recent study suggests.

Read more:
FDA warns of foot, leg amputations with J&J diabetes drug - Reuters

Posted in Diabetes | Comments Off on FDA warns of foot, leg amputations with J&J diabetes drug – Reuters

Local teen advocating for diabetes research – Journalscene.com

Posted: May 17, 2017 at 1:40 pm

Cameron Shephard is a local teen supported by her family as she raises awareness for type 1 diabetes.

The 13-year-old self-professed baby of the family with three siblings is a type 1 diabetic, a disease she was diagnosed with when she was 7 years old.

Type 1 diabetes also referred to as juvenile diabetes, though it can develop at any age is a disease in which the pancreas is not producing enough insulin, which regulates blood sugar. There is no known way to prevent Type 1 diabetes, nor is it curable. It is treatable through insulin therapy, delivered by injections or an insulin pump. Patients also regularly check to their blood sugar levels.

Cameron, who plays tennis and will be a freshman at Ashley Ridge High School next year, is trying to advocate for research through funds and awareness, and has a busy summer laid out that consists of talking to congressmen and cycling 100 miles, all to let people know why they need to care about finding a cure for diabetes.

Cameron and her family from Ridgeville refer to May 9 as her Diaversary the date when she was diagnosed.

Her mom, Lisa, a nurse, said no one else in the Shephard family has diabetes. Camerons diagnosis came as a shock to her parents.

Even as a nurse it shocked me how different it is because in nursing school they tell you so much about Type 2 diabetes, Lisa said.

At the time of her diagnosis, Camerons symptoms consisted of her drinking more and using the bathroom more, and she lost a lot of weight. She was treated at MUSC.

She honeymooned for a year a term referring to the period of time following Type 1 diabetes diagnosis when the pancreas is still producing some insulin to reduce insulin needs and assist blood sugar control.

She has endured more than 15,000 needle injections and eight hypoglycemic seizures. December was her last seizure.

Cameron has used a diabetic pump for about four years, though she sometimes goes back to using injections during the summer. She also has a CGM on her arm, which alerts her every five minutes to what her blood sugar level is so she does not have to do finger pricks as much. The CGM sends the alerts to a device which relays the information to Camerons phone, and her parents phones.

However, Cameron is not slowing down.

The teenager has had a JDRF Walk team for five years and is participating in the Ride to Cure Diabetes in September in New York. JDRF stands for the Juvenile Diabetes Research Foundation and their slogan is turning type one into type none.

The ride is a 100-mile cycling event to raise money and awareness for Type 1 diabetes research. It will be her first ride and the second one for Lisa.

Lisa said she first did the ride in 2016 on Amelia Island. She raised about $4,300 and went about 77 miles, but this year they are pledging 100 miles.

Cameron has also met with local congressmen and senators on diabetes-related issues.

Cameron was recently selected to represent South Carolina in the JDRF Childrens Congress this summer in Washington, D.C. She said she had to complete an application process and write a letter to South Carolina congressmen. There are three children representing South Carolina at the Childrens Congress and Cameron is the only one from below Columbia.

Cameron said she wanted to represent South Carolina because you dont hear about diabetes that much so just got to go make sure it is heard up in Washington.

The family will fly out July 24 to Washington for a busy two days consisting of children all of whom are living with Type 1 diabetes meeting with members of Congress to talk about what it is like living with the disease and why research to fund a cure is critical.

Cameron said she is excited and hopes to explain how we need support with everything.

Some children as young as 4 years old are going to Washington. Lisa said it helps put a face to the situation.

They see those kids and see what they have to do andit kind of pulls at their heart strings, she said.

In preparation for Childrens Congress, Cameron has made scrapbooks and a video and shell sit down with congressmen, one on one, and explain what her life is like to stay healthy.

You just got to constantly monitor it and make sure you dont go too low, Cameron said, referring to her blood sugar level, and if you do you got to have to have Skittles or glucose tab(lets) on you at all times.

Cameron carries a bag with her wherever she goes that carries all her diabetic needs. Shell have to sit out for an activity, like tennis, if her blood sugar is too low or too high.

When she grows up Cameron wants to be a pediatric nurse or maybe an endocrinologist. She said she thinks she would be able to relate with the patients.

Were definitely very proud of her, Lisa said. Ive been proud of her from day one when she was diagnosed.

Lisa said it blows her way the Cameron has never gotten down about the disease and maintains a positive attitude.

Some days Im like, Gosh, I hate this disease and shell just be like, Im fine, Lisa said.

Lisa said in Camerons lifetime, she is not sure if a cure will be found, but she thinks research will find ways to at least prevent Type 1 diabetes.

See the original post:
Local teen advocating for diabetes research - Journalscene.com

Posted in Diabetes | Comments Off on Local teen advocating for diabetes research – Journalscene.com

All-diabetes pro cycling team competes in Amgen Tour of California – KSBY San Luis Obispo News

Posted: May 17, 2017 at 1:40 pm

In a sea of professional cyclists in Stage 3 Pismo Beach of the Amgen Tour of California, riders share a common goal of crossing the finish line first. One team, in particular, has a few other things to think about it besides winning.

Team Novo Nordisk is the world's first and only all-diabetic professional racing team. Every racer has type 1 diabetes.

Australian team member, Chris Williams recalls his diagnosis. "I was in Australia doing a raceandI collapsed at the end of astage," said Williams, 35. "I thought it was dehydration so I went to the hospital and that was when I was diagnosed. The doctor told me I shouldn't cycle anymore because bike racing and diabetes is a difficult combination and I would have to give it up. I was pretty devastated."

Many athletes think they won't be able to live life the way they'd hope after diagnosis. Team Novo Nordisk wants to show the world what is possible with diabetes.

"We have riders from all over the world here. Holland, Italy, and Spain. Diabetes is everywhere," said Vassili Davidenko, Team Novo Nordisk manager.

Team Novo Nordisk hopes to inspire, educate, and empower people affected by diabetes.

"You don't have to give up on your dreams because you have diabetes. There is a common myth that diabetes stops a lot of people from a lot of things but it's not true in many cases. We're an example of that," Williams said.

Novo Nordisk's David Lozano was Tuesday's King of the Mountain.

Team Novo Nordisk athletes will compete in more than 500 competitions around the world and is striving to race in the Tour de France by 2021, which is the 100th anniversary of the discovery of insulin.

Originally posted here:
All-diabetes pro cycling team competes in Amgen Tour of California - KSBY San Luis Obispo News

Posted in Diabetes | Comments Off on All-diabetes pro cycling team competes in Amgen Tour of California – KSBY San Luis Obispo News

When OFAB gathered professionals for biotechnology – NIGERIAN TRIBUNE (press release) (blog)

Posted: May 16, 2017 at 7:44 pm

Dr Rose Gidado

Biotechnology is a modern science tool used by most countries to improve agricultural productivity, thereby eliminating hunger and ensuring food security for their populace.

Genetically Modified Organisms (GMOs) is one of the components of biotechnology which is a science tool used to engineer the genes of plants to make them behave in the manner of which they were engineered for.

GMOs have become a topical issue in Nigeria since the country have had problem of providing enough food for the populace. Recently, famine was reported to have reached some parts of the northern Nigeria.

In the quest to ensure food security in the country, some experts have called on the Nigerian government to adopt the new technology of GMOs to increase productivity.

In Nigeria, GMOs have received some criticisms from some groups, arguing the safety of the crops which the genes have been engineered.

Meanwhile, some scientists have said that the GM seeds are like other conventional seeds and does not contain any harmful or toxic contents.

Recently, the Open Forum of Agricultural Biotechnology (OFAB) gathered professionals to brainstorm on how best to convey the message of science to Nigerians.

In Nigeria, farmers who will be the users of this technology if it is adopted in the country are yet to know about the technology, most of them have not heard of the technology.

The Country Coordinator of OFAB, Dr Rose Gidado during the Agricultural Biotechnology and Biosafety Workshop for Professional Bodies Cadre, said the Forum had carried the biotechnology campaign to farmers.

She said the workshop is expected to expand the scope of OFAB and build the capacity of the participants, so that they can understand what the biotechnology is all about.

According to her the objective of the workshop is that we are trying to expand our scope, we are trying to build the capacity of the participants because science is multi faceted, so they need to understand better what we are doing so that they can join in the campaign for GMOs in Nigeria.

Gidado also said that other professional bodies are needed in the campaign, having in mind the huge benefits of this technology to Nigerian populace and the economy.

We need other professional bodies to join us in this campaign because it is all about science. This technology is all about science, it is evidence based, it is important, it can contribute to the socio-economic of Nigeria.

Meanwhile, the Director-General of the National Agricultural Seed Council, Dr Philip Ojo said before the introduction of any Genetically Modified seeds, the local capacity needs to be built.

In this light, the National Biotechnology Development Agency (NABDA), had recently trained about 20 staff of the National Agricultural Seed Council on how to identify or detect GMOs.

The Director General of NABDA, Professor Lucy Ogbadu said Nigeria cannot afford to ignore the technology, adding that another technology which may be more acceptable to Nigerians have been discovered.

She said the new technology which is called gene editing allows the scientist to work within the confines of one genetic material instead of transferring genes from one organism to another.

We cannot afford to ignore this technology, in fact, so much advances have gone beyond where we started on genetic modification, they developed what is called gene editing and we hope that gene editing will be more acceptable to Nigeria.

Explaining what gene editing is, Professor Ogbadu said we are working within the confines of the genetic materials of one organism; we are not bringing in anything from outside into the organism, so we hope that this will be more acceptable to our people.

On the acceptability of the technology, Dr Gidado said the acceptance level in Nigeria is encouraging, more people are talking for the technology, people are beginning to see why we need it.

She further said that they are carrying the farmers along in their campaign, adding that in 2 or 3 years time, the commercialisation of BT cotton and BT cowpea will commence.

One of the environmental advantage of this technology is that less chemicals and pesticides will be used in the farm, leading to less pollution of the environment with fertilizers and chemicals.

Professor Ogbadu in her presentation a the workshop said the technology has increased environmental protection through the reduced use of pesticides and toxic chemicals.

She also said GMOs improves nutrition for people, increase quality of yields, increase farm profitability through reduced cost and new product opportunity.

Much have been said about this technology, some countries have adopted this technology and used it to advance their food production. It is important that the Nigerian government look for other means to upscale our food production.

GMOs among other biotechnology is a scientific method to improve food production in Nigeria, increase yield and practice agriculture as a business, which will in turn put money in the bags of farmers and contribute the nations GDP.

Continued here:
When OFAB gathered professionals for biotechnology - NIGERIAN TRIBUNE (press release) (blog)

Posted in Biotechnology | Comments Off on When OFAB gathered professionals for biotechnology – NIGERIAN TRIBUNE (press release) (blog)

BIO Statement on the Passing of Biotechnology Giant Henri Termeer … – Business Wire (press release)

Posted: May 16, 2017 at 7:43 pm

WASHINGTON--(BUSINESS WIRE)--Henri Termeer, who passed away at the age of 71, was a founding father of modern biotechnology. He brought to his work, and to his life, a passion, a vision and a perseverance to bring ground-breaking medical innovations to those suffering from rare diseases.

Through his work, Termeer became a mentor and a role model for biotechnology entrepreneurs around the globe. The culture he created at Genzyme, and at the various institutions he worked for throughout his career, was widely seen as the gold standard for patient-focused drug development. He was a master at creating cultures where great science and great people could flourish. As the Boston Globe aptly noted, Termeer had magnetism and warmth, and a deft ability to harness top talent toward a common goal.

Termeer, who was a larger-than-life figure across the biotechnology field, was instrumental in the founding of BIO in 1993, serving as its first vice chair for health. He was named Chairman of the organization in 1996. During his tenure as Chair of BIO, and in the years that followed, Termeer was a key catalyst in the growth of the organization and in establishing BIOs position at the forefront of key policy and regulatory debates. He was an active member of BIOs Board of Directors since its founding until his death, with only a short break in his tenure. Termeer served on BIOs Executive Committee from 1993 to 2000.

Following are statements from leadership at the Biotechnology Innovation Organization (BIO):

Few people in our industry have had as profound an impact as Henri Termeer on the science of biotechnology and the patients who depend on it, said Jim Greenwood, President and CEO of BIO. He had a unique ability to inspire the men and women around him. Henri certainly was a brilliant businessman and a charismatic leader, but his burning passion was to do the unthinkable to innovate and to treat and cure rare diseases that others believed too difficult to tackle. Henri's love of his profession and the people in it was contagious. He taught us that even though our companies were sometimes competitors, our industry must speak with a united voice in the corridors of power. He was a founding father of BIO and thus the thriving ecosystem the biotechnology community enjoys today is another central part of his legacy. Henri was admired, respected and loved by all of us who were fortunate enough to know him as a colleague, a teacher, and a friend. He is an irreplaceable talent who will be long remembered and sorely missed.

Henri Termeer was a giant, said Ron Cohen, President & CEO of Acorda Therapeutics and Chair of BIO. He has left us much too soon. High among his many legacies are the tens of thousands of patients and their families who have benefited from Genzymes innovations, and the scores of biotechnology professionals whom he mentored and who have gone on to be leaders at other companies.

I had the honor of having worked at Genzyme and calling Henri Termeer amentor, said Paul Hastings, Chairman and CEO of OncoMed Pharmaceuticals and Vice Chair of BIO. He taught us all to be tough and business minded, while simultaneously taking into account how every decision impacted every person in the organization that was part of making Genzyme what it was. His focus on always doing the right thing for people and the business was something truly special. We all lost a great friend, a great mentor and awonderful role model.

From 1993-1998, Hastings served as Vice President, Global Marketing, Genzyme Therapeutics, President of Genzyme Europe and President of Genzyme Therapeutics.

"Henri has left us far too soon, but his legacy and contributions to our industry and patients with rare diseases will last forever, said John Maraganore, CEO of Alnylam Pharmaceuticals. Indeed, Henri pioneered the advancement of innovative medicines for orphan disease and inspired other companies and entrepreneurs to follow. He will be deeply missed."

"As an industry leader Henri was unparalleled and unrivaled, said Jeremy Levin, chairman and CEO of Ovid Therapeutics. As a mentor and friend, he was a foundational component of my business philosophy and career. He will be mourned and deeply missed but never forgotten."

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling innovations transforming our world and the BIO Newsletter is the organizations bi-weekly email newsletter. Subscribe to the BIO Newsletter.

Upcoming BIO Events

See more here:
BIO Statement on the Passing of Biotechnology Giant Henri Termeer ... - Business Wire (press release)

Posted in Biotechnology | Comments Off on BIO Statement on the Passing of Biotechnology Giant Henri Termeer … – Business Wire (press release)

Forge Therapeutics Attracts Biotechnology Leaders To Join … – PR Newswire (press release)

Posted: May 16, 2017 at 7:43 pm

"Forge is a very exciting, emerging life science company its novel platform and programs, its highly efficient business model, and its creative capitalization all attracted me to join the Board at such a pivotal time in the company's evolution," said John Schmid. "I look forward to providing strategic, operational and financial guidance to the management team in the coming years."

Dr. Worland added, "Multi-drug resistant bacteria 'superbugs' pose a very serious threat to human health and Forge's novel antibiotic program provides a promising solution to this global problem. I am honored to join the Forge Board and excited to work with its talented management team, advisors, and alliance and government partners as the company and technology platforms mature."

About the Forge Board of Directors

Forge's Board of Directors is a well-balanced composition of San Diego biotechnology industry veterans, global drug development experts and corporate finance leaders.

About Forge Therapeutics

Forge Therapeutics is a privately-held biopharmaceutical companydeveloping novel antibiotics to treat multi-drug resistant bacteria, or 'superbugs,' that have ignited a global health epidemic. With its proprietary chemistry approach, Forge develops small molecule inhibitors targeting metalloenzymes. Forge's lead effort is focused on LpxC, a zinc metalloenzyme found only in Gram-negative bacteria and which is essential for bacteria to grow. Forge has discovered novel small molecule inhibitors of LpxC that are potentin vitro, efficaciousin vivo, and effective against drug resistant Gram-negative bacteria 'superbugs.' To complement its innovative approach to drug discovery, Forge hasa capital efficient business model that utilizes a mix of non-dilutive and traditional funding sources to advance itsprograms, including LpxC. Forge has formed a strategic alliance with leading drug discovery alliance and development partnership company Evotec AG and has been awarded multiple government awards to address the global 'superbug' epidemic. In addition, Forge has amassed a rich intellectual property estate on metalloprotein inhibitors to protect its technology and pipeline. For further information, please visit the company's websitewww.ForgeTherapeutics.com and follow us on Twitter @ForgeThera.

Forge Company Contact:Info@ForgeTherapeutics.com

Forge Media Contact:Amy Conrad Juniper Point amy@juniper-point.com 858-366-3243

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/forge-therapeutics-attracts-biotechnology-leaders-to-join-expanded-board-of-directors-300458043.html

SOURCE Forge Therapeutics, Inc.

http://www.forgetherapeutics.com

Read more here:
Forge Therapeutics Attracts Biotechnology Leaders To Join ... - PR Newswire (press release)

Posted in Biotechnology | Comments Off on Forge Therapeutics Attracts Biotechnology Leaders To Join … – PR Newswire (press release)

Bookmarks on Stem Cell Genes Preserve Cell Identity – Cornell Chronicle

Posted: May 16, 2017 at 7:43 pm

Stem cells preserve their identities after cell division by using a series of protein bookmarks on their genes, according to new research published by scientists at Weill Cornell Medicine. The results may further the understanding of how certain diseases like cancer develop and could have broad clinical implications for preventing disease.

Pluripotent stem cells (PSCs) are cells that have the ability to transform into any kind of cell in the body. What type of cell each stem cell becomes called cell identity is determined by a tightly-controlled system regulated by various proteins. As these cells divide by mitosis, each so-called daughter cell produced should be the same type as its cell of origin. But during mitosis the control system is briefly disrupted, creating a window in which a cell can forget its identity and transform into a different kind of cell.

Dr. Effie Apostolou

If a cell doesnt remember what its supposed to be, it can transform into something else, even a malignant cell, saysDr. Effie Apostolou, an assistant professor of molecular biology in medicine and member of theSandra and Edward Meyer Cancer Centerat Weill Cornell Medicine. Understanding how this process is controlled is fundamental to understanding how many diseases arise.

In a paper published May 16 in Cell Reports, Dr. Apostolou and her team found that cell identity is preserved in pluripotent stem cells through a series of small modifications in proteins known as bookmarks on the cells genes. These bookmarks do not change during mitosis. So when the cell resumes its functions, such as transcription, after mitosis, this bookmark serves as a checkpoint to make sure that this process happens properly, Dr. Apostolou said. In this way, PSCs ensure that daughter cells are the same as their mother cells.

The researchers identified some proteins that were possible candidates for bookmarks and then removed those proteins from cells during the critical window in mitosis. If indeed this time window and the presence of these proteins are critical during mitosis, then the cell identity will be challenged, Dr. Apostolou said.

They found that when these mitotic bookmarks were degraded in PSCs, the cells were unable to maintain their identities: they did not reliably divide into the same kind of cell generation after generation. This tells us that these bookmarks are an important mechanism for keeping stem cells working properly, Dr. Apostolou said.

Because pluripotent stem cells hold great promise for prevention and treatment of many diseases, this finding is key, she said. Understanding cell identity is fundamental to understanding disease, as many, including cancer and some neurological diseases, are the result of cell identity being lost.

Mitosis can be either a crisis for cell identity or an opportunity for a new identity to arise she said. If we understand more about how cells maintain their identities during this process, we will better understand tumor formation and we may even be able to push stem cells into an identity that is therapeutically relevant for a given disease.

See original here:
Bookmarks on Stem Cell Genes Preserve Cell Identity - Cornell Chronicle

Posted in Cell Medicine | Comments Off on Bookmarks on Stem Cell Genes Preserve Cell Identity – Cornell Chronicle

Page 1,549«..1020..1,5481,5491,5501,551..1,5601,570..»